Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.
Bottom Line: Positive HER-2 status was not associated with any pretreatment clinicopathologic parameters (P > 0.05).Positive HER-2 status was significantly associated with poor 5-year disease-free survival (P = 0.015) and 5-year overall survival (P = 0.026).It can act as a worse prognostic factor for LARC patients.
Affiliation: Medical School of Shandong University, Jinan, China; Department of Radiation Oncology of Shandong Cancer Hospital and Institute, Jinan, China.Show MeSH
Related in: MedlinePlus
Mentions: Node status (N), HER-2 status, and depth of invasion (T) were found to be significantly correlated with 5-year DFS and OS, as listed in Table 4. The 5-year DFS of 22 patients with HER-2 positive status was significantly shorter than that of 97 patients with HER-2 negative status (P = 0.015) (Fig. 3a). In the total study population, HER-2-negative patients had significantly better OS as compared with HER-2-positive patients (P = 0.026) (Fig. 3b). Compared with the 5-FU/capecitabine group, the patients in the 5-FU/capecitabine and oxaliplatin group had longer DFS and OS, but the difference was not statistically significant (P = 0.213 and P = 0.346).
Affiliation: Medical School of Shandong University, Jinan, China; Department of Radiation Oncology of Shandong Cancer Hospital and Institute, Jinan, China.